Despite of the availability of treatment for this disease, this study is justified because no
known therapies are really curative and it is necessary to look for new treatment options to
improve the clinical outcome and prognosis of relapsed aggressive lymphoma. This study is
designed for patients not eligible for high-dose chemotherapy and autologous stem cells
transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Collaborator:
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte